A Lianne Messchendorp1, Edwin M Spithoven2, Niek F Casteleijn3, Wendy A Dam2, Jacob van den Born2, Wouter F Tonnis4, Carlo A J M Gaillard5, Esther Meijer2. 1. Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. a.l.messchendorp@umcg.nl. 2. Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 3. Department of Urology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 4. Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, The Netherlands. 5. Division of Internal Medicine and Dermatology, University Medical Center Utrecht, University of Utrecht, Utrecht, The Netherlands.
Abstract
BACKGROUND: Somatostatin (SST) inhibits intracellular cyclic adenosine monophosphate (cAMP) production and thus may modify cyst formation in autosomal dominant polycystic kidney disease (ADPKD). We investigated whether endogenous plasma SST concentration is associated with disease severity and progression in patients with ADPKD, and whether plasma SST concentrations change during treatment with a vasopressin V2 receptor antagonist or SST analogue. METHODS: In this observational study, fasting concentrations of SST were measured in 127 ADPKD patients (diagnosed upon the revised Ravine criteria) by ELISA. cAMP was measured in 24 h urine by Radio Immuno Assay. Kidney function was measured (mGFR) as 125I-iothalamate clearance, and total kidney volume was measured by MRI volumetry and adjusted for height (htTKV). Disease progression was expressed as annual change in mGFR and htTKV. Additionally, baseline versus follow-up SST concentrations were compared in ADPKD patients during vasopressin V2 receptor antagonist (tolvaptan) (n = 27) or SST analogue (lanreotide) treatment (n = 25). RESULTS: In 127 ADPKD patients, 41 ± 11 years, 44% female, eGFR 73 ± 32 ml/min/1.73m2, mGFR 75 ± 32 ml/min/1.73m2 and htTKV 826 (521-1297) ml/m, SST concentration was 48.5 (34.3-77.8) pg/ml. At baseline, SST was associated with urinary cAMP, mGFR and htTKV (p = 0.02, p = 0.004 and p = 0.02, respectively), but these associations lost significance after adjustment for age and sex or protein intake (p = 0.09, p = 0.06 and p = 0.15 respectively). Baseline SST was not associated with annual change in mGFR, or htTKV during follow-up (st. β = - 0.02, p = 0.87 and st. β = - 0.07, p = 0.54 respectively). During treatment with tolvaptan SST levels remained stable 38.2 (23.8-70.7) pg/mL vs. 39.8 (31.2-58.5) pg/mL, p = 0.85), whereas SST levels decreased significantly during treatment with lanreotide (42.5 (33.2-55.0) pg/ml vs. 29.3 (24.8-37.6), p = 0.008). CONCLUSIONS: Fasting plasma SST concentration is not associated with disease severity or progression in patients with ADPKD. Treatment with lanreotide caused a decrease in SST concentration. These data suggest that plasma SST cannot be used as a biomarker to assess prognosis in ADPKD, but leave the possibility open that change in SST concentration during lanreotide treatment may reflect therapy efficacy.
BACKGROUND:Somatostatin (SST) inhibits intracellular cyclic adenosine monophosphate (cAMP) production and thus may modify cyst formation in autosomal dominant polycystic kidney disease (ADPKD). We investigated whether endogenous plasma SST concentration is associated with disease severity and progression in patients with ADPKD, and whether plasma SST concentrations change during treatment with a vasopressin V2 receptor antagonist or SST analogue. METHODS: In this observational study, fasting concentrations of SST were measured in 127 ADPKDpatients (diagnosed upon the revised Ravine criteria) by ELISA. cAMP was measured in 24 h urine by Radio Immuno Assay. Kidney function was measured (mGFR) as 125I-iothalamate clearance, and total kidney volume was measured by MRI volumetry and adjusted for height (htTKV). Disease progression was expressed as annual change in mGFR and htTKV. Additionally, baseline versus follow-up SST concentrations were compared in ADPKDpatients during vasopressin V2 receptor antagonist (tolvaptan) (n = 27) or SST analogue (lanreotide) treatment (n = 25). RESULTS: In 127 ADPKDpatients, 41 ± 11 years, 44% female, eGFR 73 ± 32 ml/min/1.73m2, mGFR 75 ± 32 ml/min/1.73m2 and htTKV 826 (521-1297) ml/m, SST concentration was 48.5 (34.3-77.8) pg/ml. At baseline, SST was associated with urinary cAMP, mGFR and htTKV (p = 0.02, p = 0.004 and p = 0.02, respectively), but these associations lost significance after adjustment for age and sex or protein intake (p = 0.09, p = 0.06 and p = 0.15 respectively). Baseline SST was not associated with annual change in mGFR, or htTKV during follow-up (st. β = - 0.02, p = 0.87 and st. β = - 0.07, p = 0.54 respectively). During treatment with tolvaptanSST levels remained stable 38.2 (23.8-70.7) pg/mL vs. 39.8 (31.2-58.5) pg/mL, p = 0.85), whereas SST levels decreased significantly during treatment with lanreotide (42.5 (33.2-55.0) pg/ml vs. 29.3 (24.8-37.6), p = 0.008). CONCLUSIONS: Fasting plasma SST concentration is not associated with disease severity or progression in patients with ADPKD. Treatment with lanreotide caused a decrease in SST concentration. These data suggest that plasma SST cannot be used as a biomarker to assess prognosis in ADPKD, but leave the possibility open that change in SST concentration during lanreotide treatment may reflect therapy efficacy.
Authors: P Ruiz-Torres; F J Lucio; M González-Rubio; M Rodríguez-Puyol; D Rodríguez-Puyol Journal: Biochem Biophys Res Commun Date: 1993-09-15 Impact factor: 3.575
Authors: Jared J Grantham; Vicente E Torres; Arlene B Chapman; Lisa M Guay-Woodford; Kyongtae T Bae; Bernard F King; Louis H Wetzel; Deborah A Baumgarten; Phillip J Kenney; Peter C Harris; Saulo Klahr; William M Bennett; Gladys N Hirschman; Catherine M Meyers; Xiaoling Zhang; Fang Zhu; John P Miller Journal: N Engl J Med Date: 2006-05-18 Impact factor: 91.245
Authors: Wendy E Boertien; Esther Meijer; Paul E de Jong; Gert J ter Horst; Remco J Renken; Eric J van der Jagt; Peter Kappert; John Ouyang; Gerwin E Engels; Willem van Oeveren; Joachim Struck; Frank S Czerwiec; Dorothee Oberdhan; Holly B Krasa; Ron T Gansevoort Journal: Am J Kidney Dis Date: 2015-01-15 Impact factor: 8.860
Authors: Vicente E Torres; Arlene B Chapman; Olivier Devuyst; Ron T Gansevoort; Ronald D Perrone; Gary Koch; John Ouyang; Robert D McQuade; Jaime D Blais; Frank S Czerwiec; Olga Sergeyeva Journal: N Engl J Med Date: 2017-11-04 Impact factor: 91.245
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Maatje D A van Gastel; A Lianne Messchendorp; Peter Kappert; Merel A Kaatee; Marissa de Jong; Remco J Renken; Gert J Ter Horst; Shekar V K Mahesh; Ron T Gansevoort Journal: Abdom Radiol (NY) Date: 2018-05
Authors: Olivia L Butler; Monica M Mekhael; Arslan Ahmed; Daniel J Cuthbertson; D Mark Pritchard Journal: Front Endocrinol (Lausanne) Date: 2020-12-16 Impact factor: 5.555
Authors: Sara S Jdiaa; Nedaa M Husainat; Razan Mansour; Mohamad A Kalot; Kerri McGreal; Fouad T Chebib; Ronald D Perrone; Alan Yu; Reem A Mustafa Journal: Kidney Int Rep Date: 2022-07-05
Authors: Maria Isabel Del Olmo-Garcia; Stefan Prado-Wohlwend; Alexia Andres; Jose M Soriano; Pilar Bello; Juan Francisco Merino-Torres Journal: Biomedicines Date: 2021-12-01